Research programme: antisense therapeutics - Bristol-Myers Squibb/OliPass

Drug Profile

Research programme: antisense therapeutics - Bristol-Myers Squibb/OliPass

Latest Information Update: 31 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OliPass
  • Developer Bristol-Myers Squibb; OliPass
  • Class Antisense oligonucleotides; Peptide nucleic acids
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 28 Oct 2014 OliPass and Bristol-Myers Squibb sign license agreement for antisense therapeutics
  • 28 Oct 2014 Preclinical trials in Undefined indication in South Korea (unspecified route)
  • 27 Oct 2014 Preclinical trials in Undefined indication in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top